Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 07, 2016 9:18 AM ET

Biotechnology

Company Overview of Invitae Corporation

Company Overview

Invitae Corporation, a genetic information company, provides genetic diagnostics for various hereditary disorders. The company provides gene sequencing and deletion/duplication analysis for disorders in various medical specialties that include cardiology, such as long and short QT syndrome, Brugada syndrome, and hypertrophic cardiomyopathy; hereditary cancers, including breast, ovarian, and endometrial cancers, as well as colon and pancreatic cancers; pediatric genetics; neurology; and hematology. It also offers tools, such as Family History Tool that enables users to digitally build, modify, share, and save patient pedigrees, as well as assess their risks and decide on the appropriate genet...

458 Brannan Street

San Francisco, CA 94107

United States

Founded in 2012

268 Employees

Phone:

415-374-7782

Key Executives for Invitae Corporation

Chairman, Chief Executive Officer and Member of Strategy Team
Age: 57
Total Annual Compensation: $203.7K
Co-Founder, President, Chief Operating Officer, Member of Strategy Team and Director
Age: 41
Total Annual Compensation: $281.9K
Chief Commercial Officer and Member of Strategy Team
Age: 43
Total Annual Compensation: $286.6K
Compensation as of Fiscal Year 2014.

Invitae Corporation Key Developments

Invitae Corporation Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM

Invitae Corporation Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Randal W. Scott, Chairman, Chief Executive Officer and Member of Strategy Team.

Invitae Corporation Announces Expansion of Hereditary Cancer Testing Menu

Invitae Corporation announced that it has expanded its hereditary cancer genetic testing menu, now offering an even more comprehensive testing menu that covers all major hereditary cancers. The company has expanded its test menu to include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma, and skin cancers (melanoma and basal cell nevus syndrome). This expanded test menu is offered at the same price and with the same flexibility as all of company's genetic tests. In addition, the company is introducing three new, focused panels based entirely on oncology management guidelines in breast, gynecologic, and colon cancer. The company also offers epidermal growth factor receptor (EGFR) testing for patients with strong personal and family history of lung cancer, particularly when there is no history of environmental exposures such as tobacco smoking or radon.

Invitae Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revises Production Guidance for the Year 2015

Invitae Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenues of USD 2,187,000 compared to USD 310,000 a year ago. Loss from operations was USD 22,456,000 compared to USD 12,534,000 a year ago. Net loss was USD 22,527,000 compared to USD 12,615,000 a year ago. Basic and diluted net loss per share was USD 0.71 compared to USD 14.24 a year ago. For the nine months, the company reported revenues of USD 5,217,000 compared to USD 729,000 a year ago. Loss from operations was USD 65,186,000 compared to USD 32,069,000 a year ago. Net loss was USD 65,422,000 compared to USD 32,187,000 a year ago. Basic and diluted net loss per share was USD 2.43 compared to USD 39.27 a year ago. The company has raised its 2015 guidance for billable tests delivered to 17,000-19,000 for the year, up from its previous guidance of 16,000-18,000 billable tests delivered.

Similar Private Companies By Industry

Company Name Region
GSR Solutions LLC United States
TimTec, Inc. United States
DNA2.0, Inc. United States
G.I. Windows, Inc. United States
SpringLeaf Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Invitae Corporation, please visit invitae.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.